Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21268-21282

  Singh, Tripti ^a   Gupta, Nirzari A ^a   Xu, Su ^a   Prasad, Ram ^a   Velu, Sadanandan E ^a   Katiyar, Santosh K ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Animal model; Carcinogenesis; Chemotherapy; Oncology; Prevention; Signal transduction; Targeted therapy

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HONOKIOL; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; EGFR PROTEIN, HUMAN; LIGNAN; PLANT EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CARCINOMA CELL LINE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; FADU CELL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOUSE; NONHUMAN; OSC 19 CELL; PROTEIN EXPRESSION; RECEPTOR BINDING; SCC 1 CELL; SCC 5 CELL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL SEPARATION; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; MAGNOLIA; METABOLISM; NUDE MOUSE; PHYTOTHERAPY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BINDING SITES; BIPHENYL COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; LIGNANS; MAGNOLIA; MICE; MICE, NUDE; MOLECULAR DOCKING SIMULATION; PHYTOTHERAPY; PLANT EXTRACTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 84940734049     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4178     Document Type: Article

References (33)

1. Arbes SJ Jr, Olshan AF, Caplan DJ, Schoenbach VJ, Slade GD, Symons MJ. Factors contributing to the poorer survival of black Americans diagnosed with oral cancer (United States). Cancer Causes Control. 1999; 10: 513-523.
2. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer. 2005; 5: 127-135.
3. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL, EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357: 1695-1704.
4. Leon X, Quer M, Orus C, del Prado Venegas M. Can cure be achieved in patients with head and neck carcinoma? The problem of second neoplasm. Expert Rev Anticancer Ther. 2001; 1: 125-133.
5. Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent. 2001; 49: 72-82.
6. Perlmutter MA, Johnson JT, Snyderman CH, Cano ER, Myers EN. Functional outcomes after treatment of squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg. 2002; 128: 887-891.
7. Gellrich NC, Schimming R, Schramm A, Schmalohr D, Bremerich A, Kugler J. Pain, function and psychologic outcome before, during, and after intraoral tumor resection. J Oral Maxillofac Surg. 2002; 60: 772-777.
8. Friedlander P, Caruana S, Singh B, Shaha A, Kraus D, Harrison L, McKiernan J, Solan J, Polyak T, Shah JP. Functional status after primary surgical therapy for squamous cell carcinoma of the base of the tongue. Head Neck. 2002; 24: 111-114.
9. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck. 2001; 23: 389-398.
10. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 1996; 78: 1284-1292.
11. He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, Grandis JR. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst. 1998; 90: 1080-1087.
12. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90: 824-832.
13. Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clinical Cancer Res. 2011; 16: 2571-2579.
14. Masuda M, Wakasaki T, Toh S, Shimizu M, Adachi S. Chemoprevention of head and neck cancer by green tea extract: EGCG-the role of EGFR signaling and lipid raft. J Oncology. 2011; Article ID 540148.
15. Hahm ER, Arlotti JA, Marynowski SW, Singh SV. Honokiol, a constituent of oriental medicinal herb Magnolia officinalis, inhibits growth of PC-3 xenograft in vivo in association with apoptosis induction. Clin Cancer Res. 2008; 14: 1248-1257.
16. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G, Arbiser JL. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003; 278(37): 35501-35507.
17. Munroe ME, Arbiser JL, Bishop GA. Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol. 2007; 179: 753-763.
18. Singh T, Prasad R, Katiyar SK. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo. Epigenetics. 2013; 8: 54-65.
19. Vaid M, Sharma SD, Katiyar SK. Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: Development of topical formulation. Carcinogenesis. 2010; 31: 2004-2011.
20. Prasad R, Katiyar SK. Bioactive phytochemical proanthocyanidins inhibit growth of head and neck squamous cell carcinoma cells by targeting multiple signaling molecules. PLoS ONE. 2012; 7: e46404.
21. Katiyar SK, Meeran SM, Katiyar N, Akhtar S. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinogenesis. 2009; 48: 24-37.
22. Chao DT, Korsemeyer SJ. Bcl-2 family: regulators of cell death. Ann Rev Immunol. 1998; 16: 395-419.
23. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 1995; 7: 541-546.
24. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 2001; 26: 61-66.
25. Grana X, Reddy P. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs). Oncogene. 1995; 11: 211-219.
26. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and CIP and INK4 inhibitors. J Mol Biol. 1999; 287: 821-828.
27. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 1999; 13: 1899-1911.
28. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (London). 1990; 348: 334-336.
29. Hunter T, Pine J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 1994; 79: 573-582.
30. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992; 11: 121-139.
31. th December, 2014.
32. Jain AN. Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine. J Med Chem. 2003; 46: 499-511.
33. Miteva MA, Lee WH, Montes MO, Villoutreix BO. Fast structure-based virtual ligand screening combining FRED, DOCK, and Surflex. J Med Chem. 2005; 48: 6012-6022.